Monster Beverage Corp (MNST) concluded trading on Tuesday at a closing price of $52.56, with 3.81 million shares of worth about $200.31 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 6.53% during that period and on December 31, 2024 the price saw a gain of about 0.06%. Currently the company’s common shares owned by public are about 972.45M shares, out of which, 690.90M shares are available for trading.
Stock saw a price change of 1.35% in past 5 days and over the past one month there was a price change of -4.66%. Year-to-date (YTD), MNST shares are showing a performance of -8.77% which decreased to -8.77% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $43.32 but also hit the highest price of $61.22 during that period. The average intraday trading volume for Monster Beverage Corp shares is 5.44 million. The stock is currently trading 0.08% above its 20-day simple moving average (SMA20), while that difference is down -1.67% for SMA50 and it goes to 0.69% higher than SMA200.
Monster Beverage Corp (NASDAQ: MNST) currently have 972.45M outstanding shares and institutions hold larger chunk of about 65.97% of that.
The stock has a current market capitalization of $51.14B and its 3Y-monthly beta is at 0.74. PE ratio of stock for trailing 12 months is 33.77, while it has posted earnings per share of $1.56 in the same period. Its PEG reads 3.30 and has Quick Ratio of 2.51 while making debt-to-equity ratio of 0.14. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for MNST, volatility over the week remained 1.54% while standing at 1.93% over the month.
Stock’s fiscal year EPS is expected to rise by 6.44% while it is estimated to increase by 13.22% in next year. EPS is likely to shrink at an annualized rate of 10.22% for next 5-years, compared to annual growth of 11.87% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Exane BNP Paribas on December 19, 2024 offering an Underperform rating for the stock and assigned a target price range of between $46 and $45 to it. On November 12, 2024, Argus Reiterated their recommendations, while on November 11, 2024, TD Cowen Reiterated their ratings for the stock with a price target of $55. Stock get a Neutral rating from UBS on November 08, 2024.
